Assessment of long-term neurodevelopmental outcome following trials of medicinal products in newborn infants.

ABSTRACT: There is significant uncertainty over the role of assessment of long-term neurodevelopmental outcome (LTO) in neonatal clinical trials. A multidisciplinary working group was established to identify key issues in this area and to make recommendations about optimal approaches to evaluate LTO in therapeutic trials in newborns, which can be developed by sponsors and investigators with other key stakeholders. A key consideration for neonatal trials is the potential for the investigational product to cause widespread effects and drives the need to assess outcome in multiple organs. Thus investigators must assess whether the product has an impact on the brain and the potential for it to cause potential effects on LTO. Critically, is assessment of LTO an important direct therapeutic target or a sa

SUBMITTER: Marlow N 

PROVIDER: S-EPMC6848023 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature